Dawn Severance - TruBridge Chief Officer
| TBRG Stock | USD 16.54 0.53 3.31% |
Executive
Dawn Severance is Chief Officer of TruBridge
| Age | 54 |
| Address | 54 St. Emanuel Street, Mobile, AL, United States, 36602 |
| Phone | 251 639 8100 |
| Web | https://www.trubridge.com |
Dawn Severance Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dawn Severance against TruBridge stock is an integral part of due diligence when investing in TruBridge. Dawn Severance insider activity provides valuable insight into whether TruBridge is net buyers or sellers over its current business cycle. Note, TruBridge insiders must abide by specific rules, including filing SEC forms every time they buy or sell TruBridge'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dawn Severance over a year ago Payment of 253 shares by Dawn Severance of Computer Programs subject to Rule 16b-3 |
TruBridge Management Efficiency
The TruBridge's current Return On Tangible Assets is estimated to increase to -0.25. The TruBridge's current Return On Capital Employed is estimated to increase to -0.1. At this time, TruBridge's Non Current Assets Total are most likely to increase significantly in the upcoming years. The TruBridge's current Intangible Assets is estimated to increase to about 147.1 M, while Total Current Assets are projected to decrease to roughly 57.2 M. TruBridge's management efficiency ratios could be used to measure how well TruBridge manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Hong Chen | HUTCHMED DRC | 54 | |
| Michael Karicher | Sonida Senior Living | 54 | |
| Kin MBA | HUTCHMED DRC | 47 | |
| Adrienne Kemp | Tarsus Pharmaceuticals | N/A | |
| Arvind Sood | Amgen Inc | N/A | |
| James Myers | Spyre Therapeutics | N/A | |
| James MD | Amgen Inc | 52 | |
| Kelly Boothe | Spyre Therapeutics | N/A | |
| Meriam Kabbaj | Genfit | 50 | |
| MD JD | Tarsus Pharmaceuticals | 46 | |
| David MD | Amgen Inc | 61 | |
| Emilie Desodt | Genfit | 41 | |
| Andrew Spencer | Spyre Therapeutics | N/A | |
| Melissa Cooper | Spyre Therapeutics | N/A | |
| Matthew Busch | Amgen Inc | 50 | |
| Justin LaFountaine | Spyre Therapeutics | N/A | |
| Stefanie JD | Genfit | 42 | |
| Paul JD | Spyre Therapeutics | 59 | |
| David Ng | HUTCHMED DRC | N/A | |
| CFE CPA | Spyre Therapeutics | N/A | |
| LLM JD | Spyre Therapeutics | 41 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0064 |
TruBridge Leadership Team
Elected by the shareholders, the TruBridge's board of directors comprises two types of representatives: TruBridge inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TruBridge. The board's role is to monitor TruBridge's management team and ensure that shareholders' interests are well served. TruBridge's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TruBridge's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claire Stephens, Senior AHT | ||
| Lance Park, VP Officer | ||
| Kevin Plessner, Corporate Counsel | ||
| Robert Hinckle, Senior Services | ||
| James MBA, Senior TruBridge | ||
| Jody Harbour, Senior Management | ||
| Tracey Schroeder, Chief Officer | ||
| Amaris McComas, Chief Officer | ||
| Vita MacIntyre, Controller Officer | ||
| Christopher Fowler, President CEO | ||
| Vinay Bassi, Chief Officer | ||
| Patrick Immel, Chief Officer | ||
| David Dye, COO Director | ||
| Wes Cronkite, Chief Officer | ||
| Dawn Severance, Chief Officer |
TruBridge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TruBridge a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0064 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 417.85 M | ||||
| Shares Outstanding | 14.93 M | ||||
| Shares Owned By Insiders | 15.71 % | ||||
| Shares Owned By Institutions | 71.65 % | ||||
| Number Of Shares Shorted | 334.57 K | ||||
| Price To Book | 1.43 X |
Currently Active Assets on Macroaxis
When determining whether TruBridge is a strong investment it is important to analyze TruBridge's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TruBridge's future performance. For an informed investment choice regarding TruBridge Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TruBridge. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in TruBridge Stock please use our How to Invest in TruBridge guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TruBridge. If investors know TruBridge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TruBridge listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share (4.09) | Revenue Per Share 23.665 | Quarterly Revenue Growth 0.014 | Return On Assets (0.01) |
The market value of TruBridge is measured differently than its book value, which is the value of TruBridge that is recorded on the company's balance sheet. Investors also form their own opinion of TruBridge's value that differs from its market value or its book value, called intrinsic value, which is TruBridge's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TruBridge's market value can be influenced by many factors that don't directly affect TruBridge's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TruBridge's value and its price as these two are different measures arrived at by different means. Investors typically determine if TruBridge is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TruBridge's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.